Benzinga | Jan 6, 2022 08:14AM EST

Morgan Stanley Downgrades Adagio Therapeutics to Underweight, Lowers Price Target to $6

Morgan Stanley analyst Matthew Harrison downgrades Adagio Therapeutics (NASDAQ:ADGI) from Equal-Weight to Underweight and lowers the price target from $11 to $6.